RecruitingPhase 4NCT06497660

Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia

Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia Response: a Multicenter, Prospective, Randomized, Controlled Study

Sponsor

Fujian Medical University Union Hospital

Enrollment

496 participants

Start Date

Aug 1, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Neoadjuvant Chemotherapy Perioperative Period Anaesthesia Cardiac Function

Summary

As is well known, perioperative hemodynamic fluctuations, such as decreased blood pressure and heart rate, and cardiac dysfunction, are common complications after anesthesia. General anesthetics such as propofol and sufentanil can inhibit the central nervous system, reduce cardiac excitability and myocardial contractility, dilate peripheral blood vessels, and have a high incidence of hypotension, especially during anesthesia induction, which is particularly common in the elderly and those with underlying underlying diseases before surgery. However, the current research on the impact of neoadjuvant chemotherapy on perioperative cardiac function in patients is not specific, and there is no unified anesthesia strategy for these effects during the perioperative period. Therefore, this study aims to explore: 1. the effect of neoadjuvant chemotherapy on perioperative cardiac function in patients; 2. Improve the anesthesia plan and further explore new strategies for perioperative organ protection for such patients. The research design is a prospective, randomized, controlled trial.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Aged 18 and above;
Left ventricular ejection fraction shall not be less than 45% before neoadjuvant chemotherapy and not less than 40% after neoadjuvant chemotherapy;
The electrocardiogram shows sinus rhythm;
Acetylsalicylic acidlevel I to III;
Can understand and cooperate with the research process.

Exclusion Criteria7

Patients with congenital organic heart disease, arrhythmia requiring intervention, heart valve disease, cardiomyopathy, high atrioventricular and bundle branch block, history of myocardial infarction, severe hypertension, long-term diabetes and other diseases affecting heart function;
Patients with severe dysfunction of important organs such as liver and kidney, who are intolerant to neoadjuvant chemotherapy or surgical anesthesia;
Patients who are allergic to the drugs used in this study;
Patients with mental illness, consciousness disorders, and communication barriers;
Patients with severe coagulation dysfunction;
Patients who have used monoamine oxidase inhibitors within two weeks prior to anesthesia surgery;
Patients who refused to participate in this study.